



INTERNATIONAL CONSORTIUM *for*
INNOVATION & QUALITY
in PHARMACEUTICAL DEVELOPMENT

IQ Workshop on Bioanalysis of Antibody-Drug Conjugates (ADCs)

Proposed Program - March 13, 2026

[Spring House Innovation Park](#)

727 Norristown Rd, Building 1

Lower Gwynedd Township (Spring House), PA 19002

8:00 – 8:30 AM	Registration and Light Breakfast
8:30 – 8:45 AM	Welcome & Introduction to the Workshop Faye Vazvaei-Smith, Merck & Co., Inc. and Wenkui Li, Novartis
8:45 – 9:30 AM	KEYNOTE: Antibody Drug Conjugates (ADC) As Therapeutic Options: History, Resurgence, Clinical Pharmacology Opportunities and Challenges Tushar Garimella Ph.D., Daiichi Sankyo Inc
9:30 – 10:45 AM	Review Survey Results Faye Vazvaei-Smith, Merck & Co., Inc. and Wenkui Li, Novartis
10:45 – 11:15 AM	Q&A (Coffee & Snacks)
11:15 AM – 12:00 PM	FDA Experience Brian Booth, Ph.D., Director, Division of Cancer Pharmacology 1, Office of Clinical Pharmacology (OCP), US FDA
12:00 – 1:00 PM	Lunch
1:15 – 2:15 PM	Breakout Sessions <ul style="list-style-type: none">• Breakout 1 -Metabolism and preclinical considerations<ul style="list-style-type: none">○ Ang (Angie) Liu, J&J Innovative Medicine• Breakout 2 - PK Assay Strategy LCMS, LBA, Hybrid, DAR sensitivity<ul style="list-style-type: none">○ Weifeng Xu, Merck & Co., Inc.• Breakout 3 - PK Exposure Analysis (constituents needed for modeling and ER)<ul style="list-style-type: none">○ N Ezgi Wood, Bristol Myers Squibb• Breakout 4 - Immunogenicity Considerations<ul style="list-style-type: none">○ Ola Saad, Genentech
2:15 – 3:00 PM	Report out from Breakouts (coffee and snacks)
3:00 – 3:30 PM	Questions All participants
3:30 – 4:00 PM	Summary, Next Steps, and Thank you Faye Vazvaei-Smith, Merck & Co., Inc. and Wenkui Li, Novartis